Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS
Top Cited Papers
- 13 December 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 65 (11) , 1834-1836
- https://doi.org/10.1212/01.wnl.0000187070.35365.d7
Abstract
An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.Keywords
This publication has 8 references indexed in Scilit:
- Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's diseaseExperimental Neurology, 2004
- A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosisNeurology, 2003
- Effects of Coenzyme Q10 in Early Parkinson DiseaseArchives of Neurology, 2002
- Assay of Coenzyme Q10 in Plasma by a Single Dilution StepAnalytical Biochemistry, 2002
- Dietary Coenzyme Q10 and Vitamin E Alter the Status of These Compounds in Rat Tissues and MitochondriaJournal of Nutrition, 2000
- Mitochondria and the pathogenesis of ALS.Brain, 2000
- Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseasesMolecular Aspects of Medicine, 1997
- El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosisJournal of the Neurological Sciences, 1994